17 results on '"Latteri F"'
Search Results
2. Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dellʼItalia Meridionale) prospective study
3. Activity of a specific inhibitor, gefitinib (Iressa™, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer
4. ASSESSMENT OF MINIMAL RESIDUAL DISEASE (MRD) BY DETECTION OF SYT-SSX FUSION TRANSCRIPT (SFT) IN PERIPHERAL BLOOD (PB) OF PATIENTS WITH SYNOVIAL SARCOMA
5. Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide
6. Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study
7. SUPERIORITY OF THREE-WEEK VS. FOUR-WEEK SCHEDULE OF CISPLATIN (CDDP) AND GEMCITABINE (GEM): RESULTS OF A RANDOMIZED PHASE II STUDY.
8. Intensified CHOP regimen in aggressive lymphomas:maximal dose intensity and dose density of doxorubicin and cyclophosphamide
9. Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study
10. Dose-escalation of CHOP in non-Hodgkin's lymphoma
11. Pertuzumab, Trastuzumab, Docetaxel: a single istitution clinical exeperience for Her2 positive metastatic breast cancer (mBC)
12. Concomitantly epirubicin and trastuzumab (the Buzdar Regimen) as neo-adjuvant chemotherapy in HER2-overexpressed early breast cancer: a real-life, retrospective, mono-institutional experience
13. F56 - Concomitantly epirubicin and trastuzumab (the Buzdar Regimen) as neo-adjuvant chemotherapy in HER2-overexpressed early breast cancer: a real-life, retrospective, mono-institutional experience
14. F49 - Pertuzumab, Trastuzumab, Docetaxel: a single istitution clinical exeperience for Her2 positive metastatic breast cancer (mBC)
15. Significance of P16INK4Ahypermethylation gene in primary head/neck and colorectal tumors: it is a specific tissue event? Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study
16. Molecular detection of TP53, Ki-Ras and p16INK4Apromoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study
17. Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.